All In Biotech

Drug Trial Radar · NCT04711850

An Long-term Follow-up Trial of Kidney Tx Patients Treated With Imlifidase or PE After an AMR

A Prospective, Observational Long-term Follow-up Trial of Kidney Transplant Patients Treated With Imlifidase or Plasma Exchange After an Active/Chronic Active Antibody-Mediated Rejection Episode

Last checked: Nov 19, 2026Latest source record: May 28, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registry

Status

Terminated

Enrollment

18

Actual

Start

Jan 20, 2021

Primary completion

Mar 30, 2023

Study completion Mar 30, 2023

Sponsor

Lead sponsor
Hansa Biopharma ABIndustry
Sponsor type
Industry
First posted
Jan 15, 2021

More drug trials from this sponsor

Design

Study type
Observational
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The aim of this trial is to collect data and provide a better understanding of the long-term outcome of imlifidase treatment on active or chronic active antibody-mediated rejection (AMR) in kidney transplant recipients. This is done by collecting data during an extended follow-up period of 3 years of clinical study trial 16-HMedIdeS-12, in which patients received either imlifidase or plasma exchange (PE) as AMR treatment. Data for parameters such as kidney graft survival, patient survival, kidney function, treatment of rebound of donor specific antibodies (DSA) and anti-drug antibodies (ADAs) are collected.

Conditions

  • Kidney Transplant Rejection

Interventions

  • ImlifidaseDrug

    Immunoglobulin G degrading enzyme of Streptococcus pyogenes

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall Graft Survival at Year 3Time frame: 3 years after start of AMR treatment in feeder study (16-HMedIdeS-12)

Locations

7 sites in 3 countries. Site status is shown where the registry gives one.

  • Universitätsklinik für Innere Medizin III, Klinische Abteilung für Nephrologie MUW

    Vienna, Austria

  • Hôpital Pellegrin

    Bordeaux, France

  • CHU Grenoble Alpes - Néphrologie, dialyse et transplantation

    Grenoble, France

  • Hôpital Saint-Louis. Service de Néphrologie et Transplantation

    Paris, France

  • Hôpital Necker - Service de Néphrologie - Transplantation

    Paris, France

  • Charité-Universitätsmedizin. Dept. of Nephrology and Medical Intensive Care

    Berlin, Germany

  • Medizinische Hochschule Hannover

    Hanover, Germany

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.